Transcutaneous Administration of Imiquimod Promotes T and B Cell Differentiation into Effector Cells or Plasma Cells
We are interested in promoting the development of transcutaneous immunization using microneedle technology and attempting to apply an adjuvant with transcutaneous immunization to improve the efficacy and reduce the amount of antigen and number of administrations needed. In this study, we collected b...
Main Authors: | Sachiko Hirobe, Taki Yamasaki, Sayami Ito, Ying-Shu Quan, Fumio Kamiyama, Masashi Tachibana, Naoki Okada |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/2/385 |
Similar Items
-
Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice
by: Sachiko Hirobe, et al.
Published: (2021-12-01) -
A Perspective on Imiquimod Microneedles for Treating Warts
by: Tsu-Man Chiu, et al.
Published: (2021-04-01) -
Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment
by: Supreeda Tambunlertchai, et al.
Published: (2022-09-01) -
TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production
by: Momoko Nakao, et al.
Published: (2020-11-01) -
Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge model
by: Salma Assil, et al.
Published: (2023-07-01)